Yutiq is reported no longer available
Yutiq · fluocinolone acetonide intravitreal implant 0.18 mg · chronic non-infectious posterior-segment uveitis
No account, member ID, name, date of birth, diagnosis or email is needed to use this guide.
The Yutiq product website says the product is no longer available as of July 1, 2026.
This is an important example of why MedicineCostHelp monitors more than payer policies. A payer policy can continue to mention an older product after the manufacturer has stopped making it available. The current Yutiq website now states that the product is no longer available and tells patients to ask their doctor about options.
The current DailyMed labeling record remains published and identifies Yutiq as a 0.18 mg fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis affecting the posterior segment of the eye. A published label or old authorization pathway does not establish current commercial availability.
Do not assume an old coverage approval means the product can still be obtained.
Confirm which currently available treatment, if any, the clinician considers appropriate. MedicineCostHelp does not recommend substitutions.
If an authorization or denial names Yutiq, ask whether a new request is required for the currently selected product.
Legacy payer policies identify J7314 for Yutiq. A new product choice may have a different HCPCS code, units and authorization path.
Do not rely on an old Yutiq assistance reference. First identify the actual current product, then use that product's live assistance resources.
Coverage documents and product availability change on different schedules.
Aetna CPB 0719 currently addresses Retisert, Yutiq and Iluvien and lists J7314 for Yutiq when selection criteria are met. UnitedHealthcare has also published intravitreal corticosteroid implant coverage criteria that include Yutiq. Those documents are useful for understanding prior coverage pathways, but neither overrides the manufacturer site's current availability notice.
These products are related, but they are not interchangeable just because they contain fluocinolone.
The medicine may be only part of the problem.
Use the playbook that matches what is blocking treatment, then verify the current rule with the insurer, program or treatment site.
Approval is pending, expired or unclear.
Find the rule, status and next authorization step.
DENIEDFind the reason before appealing.
Separate medical-necessity, benefit, product and claim problems.
PREFERRED PRODUCTThe plan wants a different brand or biosimilar.
Understand product preference without making a treatment recommendation.
SITE OF CAREThe medicine may be covered, but the location is not.
Check network, site and authorization requirements.
COST TOO HIGHSeparate coverage from financial assistance.
Understand manufacturer support versus independent foundations.
CLAIM PROBLEMAuthorization was approved, but billing still failed.
Compare the approval with the product, site and claim that were billed.
Important
This page preserves a useful public path for patients whose records, old authorizations or searches still reference Yutiq. MedicineCostHelp does not recommend a replacement treatment. The treating ophthalmologist should determine the clinical option, and the insurer should confirm the coverage path for the actual current product. Sources were reviewed 2026-08-22. Verify the current official source before acting.
Reviewed August 22, 2026. Manufacturer availability notice and official/payer sources were checked for this update.